Christopher D: Personalized CRISPR Therapy and the Future of Rare Disease Care
Christopher D., Executive Specialty Sales at AbbVie, shared a post on LinkedIn:
“A baby named KJ Muldoon is why I can’t stop thinking about where medicine is headed.
KJ was born with a rare genetic disorder that stopped his liver from clearing ammonia from his blood.
The old options: a transplant, or irreversible damage. Instead, his team built a personalized CRISPR therapy for his exact mutation and delivered it straight to his liver.
It worked he’s the world’s first patient treated this way.
That case is part of a bigger shift in liver and rare disease care right now:
Base or prime editing moving from lab to bedside for hemophilia, metabolic disorders
AI catching fatty liver disease earlier and personalizing treatment
Liver organoids letting researchers test therapies before they reach a patient
The liver’s biology making it a prime target for next gen gene therapy
‘Rare disease’ used to mean ‘no good options.’ That’s changing fast.
What’s the most exciting thing you’ve seen in this space lately?
Sources:
NIH, NCATS, Baby KJ story:
Jackson Laboratory, gene editing for rare liver disorder”
Stay updated with Hemostasis Today.
-
Sep 27, 2026, 09:03Tareq Abadl: Hemoglobin Electrophoresis Patterns Across Thalassemia Syndromes
-
Sep 27, 2026, 08:33Vincent Serra: Beyond Oncology The Expanding Landscape of Immunotherapy
-
Sep 27, 2026, 08:18Tanmoy Debnath: Multiplexed Genetic Screening From a Single Newborn Blood Spot
-
Sep 27, 2026, 07:27Alexander Misono: Chronic Deep Vein Thrombosis and the Impact of Delayed Treatment
-
Sep 27, 2026, 07:17Emma Copperwaite: Back to BBTS With New Research and New Ideas
-
Sep 27, 2026, 05:58Alefiya B.: Imagine Treating a Genetic Disorder by Giving Cells the Instructions They are Missing
-
Sep 27, 2026, 04:5310 Posts Not to Miss This Week
-
Sep 27, 2026, 03:23Massimo Martino: VEN-DEC-GITMO – Advancing AML Treatment in Older Patients
-
Sep 27, 2026, 03:08Arrigo Francesco Giuseppe Cicero: Why Earlier LDL-C Lowering May Matter in Cardiovascular Prevention